IMCR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Immunocore Holdings PLC (IMCR) is not a strong buy for a beginner investor with a long-term strategy at this time. The stock shows limited upside potential based on current technicals, options sentiment, analyst ratings, and financial performance. While the company has shown revenue growth, its net income remains negative, and analysts have downgraded the stock due to concerns about its pipeline risk and limited market potential.
The MACD is positive but contracting, suggesting weakening bullish momentum. RSI is neutral at 51.351, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot point of 31.401, with resistance at 32.554 and support at 30.247. Overall, technical indicators are neutral.
Revenue increased by 24.30% YoY in Q4 2025, and EPS improved by 25.53% YoY, showing some operational progress.
Analysts have downgraded the stock, citing limited market potential for its main product and high pipeline risk. Gross margin has dropped by 2.21% YoY. Options sentiment is bearish, and the stock has a high probability of declining in the short term based on candlestick pattern analysis.
In Q4 2025, revenue increased to $104.48 million (up 24.30% YoY), net income improved but remained negative at -$30.06 million (up 26.46% YoY), and EPS increased to -0.59 (up 25.53% YoY). However, gross margin declined to 97.41% (down 2.21% YoY).
Jefferies downgraded the stock to Hold from Buy with a price target of $33, citing limited market potential and pipeline risk. Mizuho raised the price target slightly to $38 but maintained a Neutral rating.
